Obstetrics/Gynecology Topics
RSSArticles
-
What Did Supreme Court Justices Say About EMTALA and Abortion?
By the end of June, the U.S. Supreme Court will decide on whether Idaho and other states can require hospitals — through criminal laws — to turn away pregnant women experiencing a major health crisis when the best treatment for them is an abortion to end their pregnancy. Idaho presented a case that their state law preempts the Emergency Medical Treatment and Active Labor Act (EMTALA), and the federal government argued that EMTALA and the mission of protecting patients’ health and lives takes precedence.
-
EMTALA Has Protected Pregnant Patients for Three Decades — Now That Could Be at Risk
Health-preserving emergency care for pregnant women could be up to each physician’s conscience and risk-taking ability after the U.S. Supreme Court debates whether the state of Idaho is exempt from providing emergency abortion care to women who may lose their uteruses or kidneys or suffer other major health problems with delayed abortion care.
-
U.S. Supreme Court Unanimously Rejected Lawsuit Challenging FDA’s Mifepristone Decisions
Reproductive healthcare and abortion providers can exhale in relief — however briefly — because a unanimous U.S. Supreme Court decision maintains telehealth access to mifepristone, an abortion drug, in the United States.
-
Furosemide for the Management of Postpartum Hypertension
Current evidence does not support the effectiveness of furosemide in reducing the mean arterial pressure within 24 hours before discharge from delivery hospitalization or before starting antihypertensive medications, compared to a placebo.
-
What Do Clinicians Think About the American Cancer Society Cervical Cancer Screening Guidelines?
In this study of provider attitudes toward the American Cancer Society 2020 cervical cancer screening guidelines that recommend deferring screening until age 25 years and using human papilloma virus alone as the primary screening, most providers had not adopted the guidelines and were waiting for endorsement by other professional societies, such as the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology.
-
Targeting Vasomotor Symptoms with a Neurokinin-3 Receptor Antagonist
A meta-analysis of five randomized controlled studies showed that fezolinetant improved moderate-to-severe vasomotor symptoms with a pooled mean difference of 2.62 episodes per day (95% confidence interval [CI], 1.85-3.41) and had no significant adverse effects compared to placebo (odds ratio, 1.01; 95% CI, 0.84-1.22).
-
Safety of Non-Insulin Antidiabetic Medications in Early Pregnancy
A multinational cohort study of more than 50,000 pregnant people found that those with periconceptual use of non-insulin antidiabetic medications, such as sulfonylureas, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, or sodium-glucose cotransporter 2 inhibitors, did not have increased risk of congenital malformations compared to those who used insulin periconceptually.
-
Estradiol Valerate-Dienogest and VTE Risk in Combined Oral Contraceptives
A pooled analysis comparing the risk of venous thromboembolism associated with combined oral contraceptives (COC) found significantly decreased venous thromboembolism risk in estradiol valerate-dienogest COCs compared with ethinyl estradiol-levonorgestrel COCs (propensity score-stratified hazard ratio, 0.46; 95% confidence interval, 0.22-0.98).
-
Progestins and Meningioma Risk: What Do the Data Say?
The authors of this study sought to determine whether there was a relationship between progestins and central nervous system meningiomas.
-
Medication Abortion via Telehealth in the United States
A prospective study of U.S. patients obtaining medication abortion through telehealth platforms demonstrated high effectiveness (97.7%; 95% confidence interval [CI], 97.2% to 98.1%) and safety (99.8%; 95% CI, 99.6% to 99.9%).